By Diane Bartz WASHINGTON (Reuters) - The Supreme Court will hear arguments on Monday over whether big drug companies can settle patent litigation with generic rivals by making deals to keep cheaper products off the market. U.S. and state regulators say the practice costs consumers, insurers and government billions of dollars annually. The Federal Trade Commission, which has dubbed these arrangements "pay for delay," has fought them in court for more than a decade with mixed success, culminating in the case now before the Supreme Court. ...
Continue reading...
No comments:
Post a Comment